On the evening of March 17, CMS released its performance for 2024, achieving a total revenue of 7.469 billion yuan, which is a year-on-year decrease of 6.8%. The company realized a net income of 1.613 billion yuan for the year, and the normalized net income after excluding related asset impairment losses is 1.714 billion yuan. It is reported that the performance decline is mainly influenced by the implementation of national procurement. The revenue from three unselected original research drugs decreased by 28.8% year-on-year to 2.691 billion yuan in 2024. This impact is expected to be absorbed by 2025. For other core products except for these three, the majority are exclusive and innovative products. The revenue from exclusive and innovative products in 2024 is 4.551 billion yuan, an increase of 4.1% year-on-year, making up 52.8% of the total revenue.